LOCAL HEALTH DEPARTMENT DISEASE INVESTIGATION STEPS		
NC REPORTABLE DISEASE/CONDITION		INFECTIOUS AGENT (S)
HEPATITIS C, ACUTE		Hepatitis C Virus
PREPARING FOR INVESTIGATION		
KNOW THE DISEASE/CONDITION	<ul> <li>See the of Manual.</li> <li>Study AP 19<sup>th</sup> ed., p</li> <li>Refer to 0 Hepatitis (SS03); p         http://www.htm     </li> <li>Print and</li> </ul>	ase definition for Hepatitis C, Acute in the CD HA Control of Communicable Diseases Manual, pp 293 - 295. CDC MMWR: Surveillance for Acute Viral - United States, 2007. May 22, 2009; 58 pp 1 - 27. Available from: w.cdc.gov/mmwr/preview/mmwrhtml/ss5803a1. review reporting forms: confidential Disease Report (DHHS 2124) repatitis C, Acute (DHHS/EPI #60)
CONDUCTING INVESTIGATION		
COLLECT CLINICAL INFORMATION	record (acreport(s),  Obtain he service for was done  Look for e	nospitalized for this disease, obtain medical dmission note, progress note, other lab and discharge summary).  althcare provider clinical notes from date(s) of r this disease/condition. Determine why testing .  evidence in the medical record that supports dings described in the case definition.
REVIEW LABORATORY INFORMATION	Review la     Ensure al     reported v     need veri     or NAT for     predictive     not be ne     www.cdc.     Evaluate     of the case     antibody v     Hepatitis     jaundice,	boratory report(s) specific to this disease.  nti-HCV screening test positive result is with a signal to cut-of ratio. If not, test result will fication by a more specific serologic test (RIBA) r HCV RNA. If signal to cut-off ratios are of a true positive, additional confirmation may cessary. Refer to: gov/hepatitis/HCV/labtesting.htm. laboratory results to determine if requirements be definition are satisfied. Lab results for IgM to hepatitis A virus and IgM antibody to B core antigen should be negative. If no ALT must be greater than 400 IU/L.  ne healthcare provider if further testing of the
APPLY THE CASE DEFINITION	Use the contact the conta	ase definition to determine if clinical and rindings meet the case definition criteria.

## **IMPLEMENTING CONTROL MEASURES** ATTEMPT TO IDENTIFY SOURCE OF EXPOSURE Review clinical records for potential source(s) of exposure. Given the long incubation period of 2 weeks to 6 months, this may be difficult to determine. If probable source of exposure is not evident in clinical information, interview patient to obtain additional information (injection drug use, healthcare worker, exposure to blood). Review past as well as recent history. If injection drug use is a factor, individuals who may have shared needles with the case may wish to be tested and should be referred to their private medical doctor. Use the CDC website www.cdc.gov and NC Public **IMPLEMENT CONTROL MEASURES TO PREVENT** Health HCV packets to educate at risk people **DISEASE AND ADDITIONAL EXPOSURES** about the disease (HCV information packets are available upon request through the NC Division of Public Health, (919) 733-9601). Instruct the case to refrain from donating blood, plasma, organs, tissue or semen. Advise case to always cover open wounds/sores. REPORTING INVESTIGATION REPORT TO NC COMMUNICABLE Enter Part 1 and Part 2 Communicable Disease DISEASE BRANCH (CD) Reports into NC EDSS as a new event, or update the existing event if already entered. Assign event to State Disease Registrar when case investigation complete. **SPECIAL CONSIDERATIONS** MANAGEMENT OF OCCUPATIONAL EXPOSURE TO Recommendations for follow-up of occupational **HCV** HCV exposures may be found in the CDC MMWR: Updated Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. June 29, 2001; 50(RR-11); pp 21-23. Available at: www.cdc.gov/mmwr/PDF/RR/RR5011.pdf North Carolina rules (NCAC) do not specifically address post exposure testing for HCV, therefore public health does not have the authority to require testing for Hepatitis C virus.